- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Takeda changes name of PPI Kapidex to Dexilant
Wednesday, March 10 2010 | Comments
What's This?
Takeda Pharmaceuticals North America Inc. changed the name of Kapidex (dexlansoprazole), a proton pump inhibitor that is approved for several indications in gastroesophageal reflux disease, to Dexilant to minimize potential medication errors resulting from name confusion with other products.The decision for the name change was made following discussions Takeda had with the Food and Drug Administration.
The company cited reports of dispensing errors between Kapidex and AstraZeneca Plc's prostate cancer drug Casodex (bicalutamide) and Actavis Group's pain drug Kadian (morphine sulfate) extended-release capsules.
Kapidex will be available under the new brand name near the end of April.
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- Nissen fundoplication in children with GERD reduces need for antireflux medication, researchers find
- High-dose intravenous PPI regimen no better than standard-dose regimen in preventing recurrent bleeding after endoscopic hemostasis of bleeding ulcers, researchers report
- Laminar airflow ventilation during orthopedic, abdominal procedures does not prevent surgical site infections, study suggests
- Dextofisopam fails to meet primary endpoint of midstage IBS trial
- Weight loss prior to gastric bypass surgery improves outcomes in very obese patients, data indicate
- Nissen fundoplication in children with GERD reduces need for antireflux medication, researchers find
- Study supports use of adenoma detection rate as quality indicator for colonoscopy screening
- Gallbladder aspiration safe but unnecessary during elective laparoscopic cholecystectomy, researchers report
- ACG, ACC, AHA release joint statement regarding ongoing exploration of safety of PPIs in combination with clopidogrel
- High-dose intravenous PPI regimen no better than standard-dose regimen in preventing recurrent bleeding after endoscopic hemostasis of bleeding ulcers, researchers report
